Speaking at a webinar, Tagir Sitdekov, first deputy chief executive officer of RDIF, said they planned to start clinical trials here soon and that there have been no adverse side-effects so far. Five-thousand volunteers have received the jab.
Russia has started production of the vaccine at two facilities owned by the RDIF. The Gamaleya Research Institute of Epidemiology and Microbiology, too, has started production. Sitdekov said RDIF is already in talks with Indian players for contract manufacturing the Sputnik V. No deal has been signed yet. Russia is also scouting for partners in China, Korea, and Brazil, apart from India.